262 related articles for article (PubMed ID: 33788262)
21. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
22. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
23. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
24. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas.
Zhai YL; Kobayashi Y; Mori A; Orii A; Nikaido T; Konishi I; Fujii S
Int J Gynecol Pathol; 1999 Jan; 18(1):20-8. PubMed ID: 9891238
[TBL] [Abstract][Full Text] [Related]
25. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
26. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
[TBL] [Abstract][Full Text] [Related]
27. Clear-cell variant of superficial cutaneous leiomyosarcoma associated with RB1 mutation: Clinical, dermoscopic, and histopathological characteristics.
Atzori L; Pilloni L; Zanniello R; Ferreli C; Rongioletti F
J Cutan Pathol; 2020 Jun; 47(6):571-575. PubMed ID: 31999365
[TBL] [Abstract][Full Text] [Related]
28. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas.
Mittal K; Joutovsky A
Gynecol Oncol; 2007 Feb; 104(2):362-5. PubMed ID: 17011615
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
[TBL] [Abstract][Full Text] [Related]
31. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
32. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
33. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
34. Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma.
Zhai YL; Nikaido T; Orii A; Horiuchi A; Toki T; Fujii S
Gynecol Oncol; 1999 Dec; 75(3):453-9. PubMed ID: 10600306
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
36. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
37. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
38. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
[TBL] [Abstract][Full Text] [Related]
39. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.
Guijarro MV; Dahiya S; Danielson LS; Segura MF; Vales-Lara FM; Menendez S; Popiolek D; Mittal K; Wei JJ; Zavadil J; Cordon-Cardo C; Pandolfi PP; Hernando E
Am J Pathol; 2013 Jun; 182(6):2015-27. PubMed ID: 23708211
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
